viewImmuPharma PLC

ImmuPharma says US partner will meet FDA next month to gain regulator's insights on phase III lupus clinical trial

Avion Pharmaceuticals will also request the FDA consider conditional approval of the drug, whilst the final-stage trial is taking place

ImmuPharma PLC -

ImmuPharma PLC (LON:IMM) (Euronext Growth Brussels:ALIMM) has said that its partner Avion Pharmaceuticals will discuss with US regulators early next month plans for an optimised phase III study of a lupus drug developed by the UK company.

At the Type ‘A’ Meeting, to be held on December 4, the firm said Avion will ask for guidance from the US Food & Drug Administration (FDA) on key aspects of the study design, clinical endpoints and the approval process for treatment, called Lupuzor.

It will also request the FDA consider conditional approval of the drug, whilst the final-stage trial is taking place.

In a statement, ImmuPharma chief executive Dimitri Dimitriou said: "ImmuPharma and Avion are delighted that the FDA are expediting the Type 'A' Meeting for early December 2020. 

“We look forward to providing a further update to the market following confirmation from Avion of the FDA's guidance post this meeting."

Quick facts: ImmuPharma PLC

Price: 12.7 GBX

Market: AIM
Market Cap: £32.28 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...


ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3...

Dr Tim Franklin, Chief Operating Officer of ImmuPharma PLC (LON:IMM) joins Proactive London's Katie Pilbeam to discuss ImmuPharma's announcement that The US Food & Drug Administration (“FDA”) has confirmed 4th December 2020 will be the date for the Type ‘A’ Meeting Request, with Avion...

on 25/11/20

2 min read